Skip to content

BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy

Barrett's Esophagus Screening Towards Rural Referral Pathways: Screening for Esophageal Cancer in Rural Oregon Without Endoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06335966
Acronym
BEST-RPP
Enrollment
110
Registered
2024-03-28
Start date
2024-09-11
Completion date
2026-12-30
Last updated
2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Brief summary

Recent advancements in swallowable esophageal cell-collection devices (SECD) offer a safe, minimally invasive, accurate, and low-cost alternative to esophageal screening without the need for an upper endoscopy. The BEST-RPP study aims to evaluate the acceptability and feasibility of using this novel approach to screen for Barrett's Esophagus (BE) and Esophageal Carcinoma (EAC) in rural primary care clinic settings in Oregon.

Detailed description

This is a proof-of-concept observational study to pilot the use of an FDA approved swallowable esophageal cell-collection device to screen for esophageal cancer in two rural primary care clinics in Oregon. The principal investigator will work with clinic staff to gauge the current use and understanding of SECDs as screening tools for esophageal cancer and to identify 50 patients at each site to approach about SECDs as an option for screening, for a total of 100 patients. If patients provide their consent and are eligible, they will undergo SECD administration for cancer screening in their primary care clinic. The study will evaluate the feasibility of use of this diagnostic tool in rural primary care settings, patient acceptability of screening for esophageal cancer via SECD in their primary care clinics, and where there are positive cases, the efficacy of diagnostic and treatment pathways to transitioning patients to tertiary centers for full diagnostic workup.

Interventions

DEVICEScreening with swallowable esophageal cell-collection devices (SECD)

All participants who enroll in this study and provide their consent will undergo screening with an FDA approved swallowable esophageal cell-collection device (SECD)

Sponsors

OHSU Knight Cancer Institute
Lead SponsorOTHER
Kuni Foundation
CollaboratorUNKNOWN
Oregon Health and Science University
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Willing and able to comply with the protocol * Live in a rural area * Chronic GERD Dx * 3 or more of the following risk factors: Male, age \>50 years White race Tobacco smoking Obesity Family history of BE or EAC in a first-degree relative

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of the use of a SECD: Number of providers who indicate likelihood of using SECD8 monthsFeasibility of screening for esophageal cancer via SECD in rural primary care settings will be measured by data collected from Provider Post-Inservice Questionnaire, which includes, Indication of provider likelihood of using SECD as a screening tool.
Feasibility of the use of SECD: Number of providers who indicate willingness to be trained and train clinic staff8 monthsFeasibility of screening for esophageal cancer via SECD in rural primary care settings will be measured by data collected from Provider Post-Inservice Questionnaire, which includes, Indication of provider willingness to be trained and train clinic staff in SECD administration.
Feasibility of the use of SECD: Number of referrals8 monthsFeasibility of screening for esophageal cancer via SECD in rural primary care settings will be measured by data collected from number of provider referrals received for the study.
Feasibility of the use of SECD: Number enrolled8 monthsFeasibility of screening for esophageal cancer via SECD in rural primary care settings will be measured by data collected from number of patients enrolled.
Patient acceptability: Number of interested patients who schedule an appointment to be screened8 monthsAssess patient acceptability of using a SECD for screening in rural primary care settings vs tertiary care centers Acceptability will be measured by the number of interested patients who schedule an appointment to be screened via the SECD and the number of patients who come to their appointments. As well as patients who are interested in being screened via SECD at other care centers where it is offered.
Patient acceptability: Number of patients who come to their appointments8 monthsAssess patient acceptability of using a SECD for screening in rural primary care settings vs tertiary care centers Acceptability will be measured by the number of interested patients who schedule an appointment to be screened via the SECD and the number of patients who come to their appointments. As well as patients who are interested in being screened via SECD at other care centers where it is offered.
Patient acceptability: Number of patients interested in being screened via SECD at other care centers8 monthsAssess patient acceptability of using a SECD for screening in rural primary care settings vs tertiary care centers Acceptability will be measured by the number of interested patients who schedule an appointment to be screened via the SECD and the number of patients who come to their appointments. As well as patients who are interested in being screened via SECD at other care centers where it is offered.

Secondary

MeasureTime frameDescription
Access: time to full diagnostic work up for patients with positive SECD results8 monthsObserve the time, effort, and barriers patients who live in rural areas with positive SECD tests experience to complete standard - diagnostic work up at tertiary care centers

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026